A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
Public ClinicalTrials.gov record NCT07422480. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multicenter, Open-Label, Randomized Trial to Compare the Efficacy and Safety of Elritercept Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in ESA-naïve Adult Participants Who Require Red Blood Cell Transfusions
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main aim of this study is to assess how elritercept works in lowering the need for RBC (red blood cell) transfusions and how safe elritercept is when compared with epoetin alfa. Other aims are to learn if elritercept improves tiredness as reported by participants without needing RBC transfusion compared with epoetin alfa, the RBC transfusion burden and quality of life compared with epoetin alfa. The study also aims to find out the extent of the immune response to elritercept. The study will also check on the medical problems (safety) of elritercept.
Study identification
- NCT ID
- NCT07422480
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 300 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 21, 2026 (Actual)
- Primary completion
- Apr 30, 2029 (Estimated)
- Completion
- Oct 1, 2033 (Estimated)
- Last update posted
- Sep 18, 2026
2026 – 2033
United States locations
- U.S. sites
- 31
- U.S. states
- 19
- U.S. cities
- 29
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Banner MD Anderson Cancer Center | Gilbert | Arizona | 85234 | Not yet recruiting |
| City of Hope - Comprehensive Cancer Center (CCC) | Duarte | California | 91010 | Not yet recruiting |
| Providence Medical Group | Santa Rosa | California | 95403 | Not yet recruiting |
| Cancer & Blood Research Center | Whittier | California | 90270 | Not yet recruiting |
| Yale | New Haven | Connecticut | 06510 | Not yet recruiting |
| University of Miami | Miami | Florida | 33136 | Not yet recruiting |
| BRCR Medical Center Inc | Tamarac | Florida | 33321 | Recruiting |
| Moffitt Cancer Center | Tampa | Florida | 33612 | Not yet recruiting |
| Emory University | Atlanta | Georgia | 30322 | Recruiting |
| Orchard Healthcare Research Inc. (OHR) - Skokie | Skokie | Illinois | 60077 | Recruiting |
| Norton Cancer Institute | Louisville | Kentucky | 40207 | Recruiting |
| Epic Medical Research | Monroe | Louisiana | 71201 | Not yet recruiting |
| Epic Medical Research - Shreveport | Shreveport | Louisiana | 71106 | Not yet recruiting |
| The Cancer and Hematology Centers | Grand Rapids | Michigan | 49503 | Not yet recruiting |
| American Oncology Partners P.A. MidAmerica Cancer Care | Kansas City | Missouri | 64132 | Recruiting |
| Hematology Oncology Associates of Rockland | Nyack | New York | 10960 | Not yet recruiting |
| Albert Einstein College - Montefiore | The Bronx | New York | 10467 | Recruiting |
| Novant Health Care Institute | Winston-Salem | North Carolina | 27106 | Not yet recruiting |
| Cleveland clinic OH | Cleveland | Ohio | 44195 | Not yet recruiting |
| Thomas Jefferson University | Philadelphia | Pennsylvania | 19107 | Not yet recruiting |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | Recruiting |
| Tennessee Oncology, PLLC | Nashville | Tennessee | 37203 | Recruiting |
| World Research Link | Baytown | Texas | 77521 | Recruiting |
| Texas Oncology - Denton | Denton | Texas | 76201 | Not yet recruiting |
| The Center for Cancer and Blood Disorders | Fort Worth | Texas | 76104 | Recruiting |
| The University of Texas-MD Anderson Cancer Center - Leukemia Center | Houston | Texas | 77030 | Recruiting |
| LUMI Research | Houston | Texas | 77090 | Recruiting |
| Renovatio Clinical | The Woodlands | Texas | 77380 | Not yet recruiting |
| Huntsman Cancer Institute | Salt Lake City | Utah | 84124 | Not yet recruiting |
| Virginia Commonwealth University (VCU)-Medical Center - North Hospital | Richmond | Virginia | 23298 | Not yet recruiting |
| West Virginia University Cancer Institute | Wheeling | West Virginia | 26003 | Not yet recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 131 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07422480, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 18, 2026 · Synced Oct 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07422480 live on ClinicalTrials.gov.